Oluwaseun FATOBA

Dr. Oluwaseun FATOBA

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
OFOluwaseun FATOBA
Oluwaseun FATOBA
TITakahide Itokazu
Takahide Itokazu
TYToshihide Yamashita
Toshihide Yamashita
Chronic microglial activation is associated with the pathogenesis of several CNS disorders. Microglia show phenotypic diversity and functional complexity in diseased CNS. Thus, understanding the pathology-specific heterogeneity of microglial behavior is crucial for the future development of microglia-modulating therapy for variety of CNS disorders. This review summarizes up-to-date knowledge on how microglia contribute to CNS homeostasis during development and throughout adulthood. We discuss the heterogeneity of microglial phenotypes in the context of CNS disorders with an emphasis on neurodegenerative diseases, demyelinating diseases, CNS trauma, and epilepsy. We conclude this review with a discussion about the disease-specific heterogeneity of microglial function and how it could be exploited for therapeutic intervention.

18 February 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
OFOluwaseun FATOBA
Oluwaseun FATOBA
TITakahide Itokazu
Takahide Itokazu
TYToshihide Yamashita
Toshihide Yamashita
The complement system, an essential tightly regulated innate immune system, is a key regulator of normal central nervous system (CNS) development and function. However, aberrant complement component expression and activation in the brain may culminate into marked neuroinflammatory response, neurodegenerative processes and cognitive impairment. Over the years, complement‐mediated neuroinflammatory responses and complement‐driven neurodegeneration have been increasingly implicated in the pathogenesis of a wide spectrum of CNS disorders. This review describes how complement system contributes to normal brain development and function. We also discuss how pathologic insults such as misfolded proteins, lipid droplet/lipid droplet‐associated protein or glycosaminoglycan accumulation could trigger complement‐mediated neuroinflammatory responses and neurodegenerative process in neurodegenerative proteinopathies, age‐related macular degeneration and neurodegenerative lysosomal storage disorders.

13 April 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TVTobias Vöpel
Tobias Vöpel
KBKenny Bravo-Rodriguez
Kenny Bravo-Rodriguez
SMSumit Mittal
Sumit Mittal
SVShivang Vachharajani
Shivang Vachharajani
DGDavid Gnutt
David Gnutt
EGElsa Sanchez Garcia
Elsa Sanchez Garcia

10 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GEGisa Ellrichmann
Gisa Ellrichmann
ABAlina Blusch
Alina Blusch
OFOluwaseun FATOBA
Oluwaseun FATOBA
JBJanine Brunner
Janine Brunner
CRChristiane Reick
Christiane Reick
RGRalf Gold
Ralf Gold
The transgenic mouse model R6/2 exhibits Huntington’s disease (HD)-like deficits and basic pathophysiological similarities. We also used the pheochromocytoma-12 (PC12)-cell-line-model to investigate the effect of laquinimod on metabolic activity. Laquinimod is an orally administered immunomodulatory substance currently under development for the treatment of multiple sclerosis (MS) and HD. As an essential effect, increased levels of BDNF were observed. Therefore, we investigated the therapeutic efficacy of laquinimod in the R6/2 model, focusing on its neuroprotective capacity. Weight course and survival were not influenced by laquinimod. Neither were any metabolic effects seen in an inducible PC12-cell-line model of HD. As a positive effect, motor functions of R6/2 mice at the age of 12 weeks significantly improved. Preservation of morphologically intact neurons was found after treatment in the striatum, as revealed by NeuN, DARPP-32, and ubiquitin. Biochemical analysis showed a significant increase in the brain-derived neurotrophic factor (BDNF) level in striatal but not in cortical neurons. The number of mutant huntingtin (mhtt) and inducible nitric oxide synthase (iNOS) positive cells was reduced in both the striatum and motor cortex following treatment. These findings suggest that laquinimod could provide a mild effect on motor function and striatal histopathology, but not on survival. Besides influences on the immune system, influence on BDNF-dependent pathways in HD are discussed.

25 February 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
OFOluwaseun FATOBA
Oluwaseun FATOBA
YOYosuke Ohtake
Yosuke Ohtake
TITakahide Itokazu
Takahide Itokazu
TYToshihide Yamashita
Toshihide Yamashita
Modulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no efficacy in alleviating disease burden and restoring functional capacity. Marked immune system activation and neuroinflammation are important features and prodromal signs in polyQ repeat disorders and α-synucleinopathies. This review describes the current status and future directions of immunotherapies in proteinopathy-induced neurodegeneration with emphasis on preclinical and clinical efficacies of several anti-inflammatory compounds and antibody-based therapies for the treatment of Huntington's disease and α-synucleinopathies. The review concludes with how disease modification and functional restoration could be achieved by using targeted multimodality therapy to target multiple factors.

1 April 2018 in Experimental Neurology
Verified
Journal Article
Closed access
OFOluwaseun FATOBA
Oluwaseun FATOBA
EKEugen Kloster
Eugen Kloster
CRChristiane Reick
Christiane Reick
Carsten SaftCarsten Saft
Carsten Saft
RGRalf Gold
Ralf Gold
GEGisa Ellrichmann
Gisa Ellrichmann